MA51139A - Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer - Google Patents
Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancerInfo
- Publication number
- MA51139A MA51139A MA051139A MA51139A MA51139A MA 51139 A MA51139 A MA 51139A MA 051139 A MA051139 A MA 051139A MA 51139 A MA51139 A MA 51139A MA 51139 A MA51139 A MA 51139A
- Authority
- MA
- Morocco
- Prior art keywords
- piperidinocarbonylmethyl
- cancer
- treatment
- oxopiperazine derivatives
- oxopiperazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599336P | 2017-12-15 | 2017-12-15 | |
| CH1522018 | 2018-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51139A true MA51139A (fr) | 2020-10-21 |
Family
ID=65003562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051139A MA51139A (fr) | 2017-12-15 | 2018-12-17 | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10710975B2 (fr) |
| EP (1) | EP3724178B1 (fr) |
| JP (1) | JP7307744B2 (fr) |
| KR (2) | KR102811956B1 (fr) |
| CN (1) | CN111788191B (fr) |
| AU (1) | AU2018386327B2 (fr) |
| BR (1) | BR112020011925A2 (fr) |
| CA (1) | CA3085481A1 (fr) |
| IL (1) | IL275337B2 (fr) |
| MA (1) | MA51139A (fr) |
| MX (1) | MX2020006219A (fr) |
| RU (1) | RU2020123261A (fr) |
| SG (1) | SG11202005365WA (fr) |
| TW (1) | TWI810229B (fr) |
| WO (1) | WO2019118973A1 (fr) |
| ZA (1) | ZA202003554B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202005365WA (en) * | 2017-12-15 | 2020-07-29 | Inthera Bioscience AG | 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer |
| WO2020048831A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one |
| WO2020048827A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de la 1,3,9-triazaspiro[5.5]undécan-2-one |
| WO2020048826A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de la 1-oxa-3,9-diazaspiro[5.5]undécan-2-one substituée en position 5 |
| TW202024083A (zh) | 2018-09-03 | 2020-07-01 | 德商拜耳廠股份有限公司 | 3,9-二氮雜螺[5.5]十一烷化合物 |
| WO2020048830A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one |
| WO2020048828A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane |
| WO2021144302A1 (fr) * | 2020-01-13 | 2021-07-22 | Inthera Bioscience AG | Biomarqueurs pour déterminer la sensibilité à des dérivés d'oxopipérazine et leurs méthodes d'utilisation |
| EP4168014A1 (fr) * | 2020-06-19 | 2023-04-26 | Inthera Bioscience AG | Dérivés d'oxopipérazine pour le traitement du cancer |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| EP4554947A1 (fr) * | 2022-07-15 | 2025-05-21 | Sutro Biopharma, Inc. | Charges utiles-lieurs clivables par une protéase/enzyme et conjugués protéiques |
| EP4587430A1 (fr) * | 2022-09-16 | 2025-07-23 | Syngenta Crop Protection AG | Composés amines cycliques à action pesticide |
| AU2024281858A1 (en) | 2023-05-26 | 2025-11-27 | Inthera Bioscience AG | Oxopiperazine derivatives for the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885995A (en) | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ES2335092T3 (es) | 2001-08-24 | 2010-03-22 | Yale University | Compuestos de piperazinona como agentes antitumorales y anticancer. |
| PE20030705A1 (es) | 2001-10-17 | 2003-08-21 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes |
| JP4614770B2 (ja) * | 2002-11-18 | 2011-01-19 | シェーリング コーポレイション | アンドロゲン依存性疾患を処置するための１７β−ヒドロキシステロイドデヒドロゲナーゼタイプ３インヒビター |
| JP2006516632A (ja) | 2003-01-30 | 2006-07-06 | スミスクライン・ビーチャム・コーポレイション | Ｎｋ−２およびｎｋ−３受容体アンタゴニストとしてのキノリン誘導体 |
| GB0314733D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| WO2007016496A2 (fr) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipipérazinyl cétones et analogues apparentés |
| CN101341123A (zh) * | 2005-12-21 | 2009-01-07 | 因塞特公司 | 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺 |
| WO2012021144A1 (fr) | 2010-08-12 | 2012-02-16 | New York University | Oligooxopipérazines et procédés pour leur préparation et leur utilisation |
| JP2014514321A (ja) * | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子１受容体阻害剤 |
| PT2807153T (pt) | 2012-01-25 | 2020-06-18 | Novartis Ag | Compostos heterocíclicos e métodos para seu uso |
| CN104334541A (zh) | 2012-02-16 | 2015-02-04 | 纽约大学 | 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制 |
| EP2945631A4 (fr) | 2013-01-19 | 2016-06-29 | Univ New York | Oligooxopipérazines pour la réactivation du p53 |
| US11180481B2 (en) | 2014-04-15 | 2021-11-23 | New York University | Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction |
| AU2015264201A1 (en) * | 2014-05-21 | 2017-01-12 | New York University | Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression |
| SG11202005365WA (en) | 2017-12-15 | 2020-07-29 | Inthera Bioscience AG | 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer |
| WO2021144302A1 (fr) | 2020-01-13 | 2021-07-22 | Inthera Bioscience AG | Biomarqueurs pour déterminer la sensibilité à des dérivés d'oxopipérazine et leurs méthodes d'utilisation |
| EP4168014A1 (fr) | 2020-06-19 | 2023-04-26 | Inthera Bioscience AG | Dérivés d'oxopipérazine pour le traitement du cancer |
-
2018
- 2018-12-17 SG SG11202005365WA patent/SG11202005365WA/en unknown
- 2018-12-17 JP JP2020552682A patent/JP7307744B2/ja active Active
- 2018-12-17 EP EP18830663.3A patent/EP3724178B1/fr active Active
- 2018-12-17 WO PCT/US2018/066027 patent/WO2019118973A1/fr not_active Ceased
- 2018-12-17 TW TW107145504A patent/TWI810229B/zh active
- 2018-12-17 CA CA3085481A patent/CA3085481A1/fr active Pending
- 2018-12-17 RU RU2020123261A patent/RU2020123261A/ru unknown
- 2018-12-17 KR KR1020207020485A patent/KR102811956B1/ko active Active
- 2018-12-17 CN CN201880089454.7A patent/CN111788191B/zh active Active
- 2018-12-17 BR BR112020011925-3A patent/BR112020011925A2/pt unknown
- 2018-12-17 MA MA051139A patent/MA51139A/fr unknown
- 2018-12-17 KR KR1020257016396A patent/KR20250078596A/ko active Pending
- 2018-12-17 AU AU2018386327A patent/AU2018386327B2/en active Active
- 2018-12-17 MX MX2020006219A patent/MX2020006219A/es unknown
- 2018-12-17 IL IL275337A patent/IL275337B2/en unknown
- 2018-12-17 US US16/222,479 patent/US10710975B2/en active Active
-
2020
- 2020-06-03 US US16/891,417 patent/US11306068B2/en active Active
- 2020-06-12 ZA ZA2020/03554A patent/ZA202003554B/en unknown
-
2022
- 2022-01-07 US US17/570,959 patent/US12012393B2/en active Active
-
2024
- 2024-04-30 US US18/650,360 patent/US20250115571A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220213057A1 (en) | 2022-07-07 |
| AU2018386327B2 (en) | 2023-04-13 |
| IL275337A (en) | 2020-07-30 |
| KR102811956B1 (ko) | 2025-05-23 |
| US20250115571A1 (en) | 2025-04-10 |
| CA3085481A1 (fr) | 2019-06-20 |
| SG11202005365WA (en) | 2020-07-29 |
| WO2019118973A1 (fr) | 2019-06-20 |
| TWI810229B (zh) | 2023-08-01 |
| JP2021506973A (ja) | 2021-02-22 |
| US10710975B2 (en) | 2020-07-14 |
| KR20250078596A (ko) | 2025-06-02 |
| EP3724178A1 (fr) | 2020-10-21 |
| IL275337B1 (en) | 2024-02-01 |
| CN111788191A (zh) | 2020-10-16 |
| AU2018386327A1 (en) | 2020-06-25 |
| BR112020011925A2 (pt) | 2020-11-24 |
| ZA202003554B (en) | 2024-11-27 |
| US20200308139A1 (en) | 2020-10-01 |
| CN111788191B (zh) | 2024-06-04 |
| US12012393B2 (en) | 2024-06-18 |
| RU2020123261A3 (fr) | 2022-02-16 |
| EP3724178B1 (fr) | 2024-05-01 |
| IL275337B2 (en) | 2024-06-01 |
| KR20200101397A (ko) | 2020-08-27 |
| TW201930286A (zh) | 2019-08-01 |
| RU2020123261A (ru) | 2022-01-17 |
| US11306068B2 (en) | 2022-04-19 |
| US20190185449A1 (en) | 2019-06-20 |
| JP7307744B2 (ja) | 2023-07-12 |
| MX2020006219A (es) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3781564C0 (fr) | Dérivés de pyridazine pour le traitement du cancer | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| EP3431105A4 (fr) | Composition médicinale pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| EP3634417C0 (fr) | Dérivés quinazoline-pyrazole pour le traitement de troubles liés au cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3432927A4 (fr) | Inhibiteurs trispécifiques pour le traitement du cancer | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3452060A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3436002A4 (fr) | Combinaisons pharmaceutiques pour le traitement du cancer | |
| EP3397963A4 (fr) | Inhibition de mapk p38 pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3400010A4 (fr) | Combinaisons anti-her2 pour le traitement des tumeurs | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3362066A4 (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3454896A4 (fr) | Dérivés hétérocycliques pour le traitement de rsv | |
| EP3541417A4 (fr) | Immunothérapies d'association pour le traitement du cancer | |
| EP3383407A4 (fr) | Conjugués de cytarabine pour le traitement du cancer | |
| EP3443962A4 (fr) | Dérivé de quinoline pour le traitement du cancer de l'estomac | |
| EP3793544A4 (fr) | Compositions bifonctionnelles pour le traitement du cancer |